

Uppsala
July 26, 2007

INTERIM REPORT JANUARY-JUNE 2007

- Group revenues from sales of goods and royalties amounted to 665.0 (686.2) MSEK during the period.
- Growth within the Esthetics product area was 17 percent and revenues amounted to 537.1 (460.8) MSEK.
- Operating income amounted to 318.2 (212.9) MSEK and the operating margin was 47.9 (34.7) percent.
- Income after tax amounted to 284.0 (151.4) MSEK.
- Earnings per share after full dilution were 2.86 (1.53) SEK.
- RESTYLANE Perlane approved for sales in USA. In connection with approval, Q-Med received 29.1 MUSD from Medicis.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company primarily develops, produces, markets and sells medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX Nordic Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med AB.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Tel: 018-474 90 00, Fax: 018-474 90 01
info@q-med.com, www.q-med.com, Corporate identity number: 556258-6882

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

GROUP REVENUES FROM SALES OF GOODS AND ROYALTIES

Total revenues from sales of goods and royalties during the period amounted to 665.0 (686.2) MSEK, of which royalties regarding DUROLANE were 6.2 (73.5) MSEK. The royalties figure for 2006 includes a one-time payment of 73.5 MSEK regarding DUROLANE. Q-Med's sales of goods increased by 8 percent during the period to 658.8 (612.7) MSEK, compared with the previous year.

Sales growth within the Esthetics product area was positive in all major markets and amounted to 17 percent during the period. Total revenues, including royalties, for the Hospital Healthcare product area decreased by 43 percent. Most of the decrease within this product area is, however, attributable to the change in the manner of distribution of DUROLANE and to last year's one-time payment of 73.5 MSEK.

Fluctuations in exchange rates negatively affected the valuation of sales revenues by 18.3 MSEK, of which 8.3 MSEK was during the second quarter.

During the second quarter sales of goods increased by 9 percent to 361.5 (330.5) MSEK, compared with the previous year. Sales within Esthetics increased by 18 percent. Total revenues from sales of goods and royalties amounted to 364.7 (404.0) MSEK during the second quarter (including the one-time payment in 2006).

Revenues from sales of goods per geographic area and product area


January - June

| (MSEK) | Product area | | | | | | | | |
|-------------------|--------------|--------------|------------|---------------------|--------------|-------------|--------------|--------------|-----------|
| | Esthetics | | | Hospital Healthcare | | | Total | | |
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % |
| Nordic countries | 24.3 | 21.2 | 15% | 3.2 | 4.5 | -29% | 27.5 | 25.7 | 7% |
| Rest of Europe | 242.0 | 223.2 | 8% | 42.5 | 59.8 | -29% | 284.5 | 283.0 | 1% |
| North America | 87.6 | 65.7 | 33% | 73.2 | 84.1 | -13% | 160.8 | 149.8 | 7% |
| Latin America | 18.4 | 11.2 | 64% | 0.3 | 0.1 | 200% | 18.7 | 11.3 | 65% |
| Asia | 140.2 | 111.5 | 26% | 2.5 | 3.4 | -26% | 142.7 | 114.9 | 24% |
| Rest of the world | 24.6 | 28.0 | -12% | 0.0 | 0.0 | - | 24.6 | 28.0 | -12% |
| Total | 537.1 | 460.8 | 17% | 121.7 | 151.9 | -20% | 658.8 | 612.7 | 8% |

April - June

| (MSEK) | Product area | | | | | | | | |
|-------------------|--------------|--------------|------------|---------------------|-------------|-------------|--------------|--------------|-----------|
| | Esthetics | | | Hospital Healthcare | | | Total | | |
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % |
| Nordic countries | 14.4 | 11.5 | 25% | 1.4 | 1.4 | 0% | 15.8 | 12.9 | 22% |
| Rest of Europe | 129.0 | 123.3 | 5% | 22.6 | 29.6 | -24% | 151.6 | 152.9 | -1% |
| North America | 55.7 | 38.2 | 46% | 38.6 | 44.8 | -14% | 94.3 | 83.0 | 14% |
| Latin America | 10.4 | 7.2 | 44% | 0.3 | 0.1 | 200% | 10.7 | 7.3 | 47% |
| Asia | 74.4 | 57.4 | 30% | 1.4 | 1.8 | -22% | 75.8 | 59.2 | 28% |
| Rest of the world | 13.3 | 15.2 | -13% | 0.0 | 0.0 | - | 13.3 | 15.2 | -13% |
| Total | 297.2 | 252.8 | 18% | 64.3 | 77.7 | -17% | 361.5 | 330.5 | 9% |

Revenues from sales and royalties; rolling 12 months



The above graph includes the effect of the one-time payment of royalties of 73.5 MSEK with regard to DUROLANE. This was received in June 2006.

GROUP INCOME

The Group's gross income during the period amounted to 571.3 (603.0) MSEK. The gross margin for sales of goods amounted to 86 (86) percent. When RESTYLANE Perlane was approved in the USA Q-Med received 29.1 MUSD (197.4 MSEK) from Medicis. This constituted the final supplementary purchase sum from the agreement that was entered into in 2003. This revenue is recorded in the row Other operating revenues.

Marketing and selling expenses amounted to 265.1 (247.8) MSEK during the period, which corresponds to 40 (36) percent of sales. In the second quarter these expenses amounted to 142.2 (131.5) MSEK.

Costs for research and development amounted to 139.8 (95.3) MSEK during the period, which corresponds to 21 (14) percent of the revenues. In the second quarter these costs amounted to 86.9 (42.4) MSEK. In the second quarter a provision of 29.4 MSEK was carried as an expense with regard to the registration of RESTYLANE Perlane in the USA. The net effect of the revenue from Medicis regarding RESTYLANE Perlane thereby amounted to 167.4 MSEK.

Depreciation and amortization amounted to 24.3 (21.4) MSEK, of which 12.2 (10.6) MSEK was in the second quarter.

Net financial income amounted to 3.1 (2.0) MSEK during the period. Fluctuations in exchange rates affected net financial income by 0.5 (-0.2) MSEK. Net income for the period after tax amounted to 284.0 (151.4) MSEK. Net income after tax in the second quarter was 242.3 (112.4) MSEK.

INVESTMENTS AND CASH FLOW

The cash flow from operating activities amounted to 64.6 (108.4) MSEK during the first six months of the year.

The cash flow from investing activities amounted to -138.9 (-67.4) MSEK. This includes the payment of 197.4 MSEK from Medicis. The investments during the period are primarily for the construction of the new office building, which was first used in June this year.

In May a dividend of 198.7 MSEK was paid to the shareholders in accordance with the decision of the Annual General Meeting. In all the cash flow was 5.9 (-32.9) MSEK and at the end of the period Q-Med had liquid funds of 479.5 MSEK.


ESTHETICS PRODUCT AREA

It is primarily a family of products covered by the RESTYLANE trademark that is marketed within the Esthetics product area today. These products are used in the treatment of wrinkles and folds in the face and for the contouring and sculpting of the face and lips. The Esthetics product area comprises approximately 80 percent of Q-Med's sales.

| (MSEK) | January - June | | | April - June | | | Whole year 2006 |
|------------------------------|----------------|-------|-------|--------------|-------|-------|--------------------|
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | |
| Revenues from sales of goods | 537.1 | 460.8 | 17% | 297.2 | 252.8 | 18% | 950.6 |
| Operating income* | 388.6 | 200.6 | 94% | 300.3 | 117.5 | 156% | 380.0 |
| Operating margin | 72% | 44% | | 101% | 46% | | 40% |

* 2007 including the net effect of the one-time payment from Medicis, 167.4 MSEK.

Sales within the product area increased by 17 percent during the first six months of the year and amounted to 537.1 (460.8) MSEK, of which 297.2 (252.8) MSEK was during the second quarter. Operating income was 388.6 (200.6) MSEK, of which 300.3 (117.5) MSEK was during the second quarter. The operating margin amounted to 72 (44) percent. Fluctuations in exchange rates negatively affected the valuation of sales revenues by 11.7 MSEK.



Sales in Europe increased by 6 percent during the second quarter compared with the corresponding period in 2006. Greece, Russia and Spain are markets that developed particularly well.

Sales to Medicis, Q-Med's partner in North America, increased by 46 percent in the second quarter, compared with the corresponding period the previous year. At the beginning of May RESTYLANE Perlane was approved for sales in the USA. Due to this Q-Med received 29.1 MUSD from Medicis. This payment is the last supplementary purchase sum from the agreement that was entered into in 2003. The transaction has thereby generated a total of 160 MUSD in addition to day-to-day revenues from sales of goods. In connection with this payment, the research and development costs of 29.4 MSEK that Q-Med has had in connection with the registration process have also be carried as an expense.

Growth in Latin America continued to be high during the period. As from the second quarter of 2007 all importation and sales in Brazil have been carried out via Q-Med's own company and sales increased by 138 percent compared with the corresponding period the previous year. Columbia, Argentina and Mexico also displayed good growth.

Growth in Asia was good. South Korea and Taiwan displayed particularly great growth. All shipments of products to the distributors in Asia are now made via Q-Med's subsidiary in Hong Kong. The registration process concerning RESTYLANE is ongoing in China.



RESTYLANE och RESTYLANE Perlane are the largest products within the Esthetics product area. Sales of RESTYLANE Perlane increased considerably in connection with the approval of the product for sales in the USA. RESTYLANE Vital and MACROLANE are products within the development areas of hydro balance and body contouring. Sales of RESTYLANE Vital, which are greatest in Spain and Italy, increased by 50 per cent compared with the corresponding period the previous year.

HOSPITAL HEALTHCARE PRODUCT AREA

The Hospital Healthcare product area comprises Q-Med's products for medical indications – DEFLUX, which is used in the treatment of vesicoureteral reflux (VUR) in children, ZUIDEX, which is used to treat stress urinary incontinence in women, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, SOLESTA, for the treatment of fecal incontinence, and COSMOFER, an iron preparation for intravenous/intramuscular usage. The Hospital Healthcare product area comprises approximately 20 percent of Q-Med's sales.

| Revenues from sales of goods (MSEK) | January - June | | | April - June | | | Whole year 2006 |
|-------------------------------------|----------------|-------|-------|--------------|-------|-------|--------------------|
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | |
| DEFLUX | 89.8 | 99.5 | -10% | 46.7 | 52.2 | -11% | 198.0 |
| DUROLANE | 21.9 | 38.5 | -43% | 11.8 | 19.6 | -40% | 60.0 |
| ZUIDEX | 9.4 | 13.9 | -32% | 5.2 | 5.9 | -12% | 19.1 |
| SOLESTA | 0.4 | 0.0 | - | 0.4 | 0.0 | - | 0.0 |
| COSMOFER | 0.2 | 0.0 | - | 0.2 | 0.0 | - | 0.0 |
| Total revenues from sales of goods | 121.7 | 151.9 | -20% | 64.3 | 77.7 | -17% | 277.1 |
| Royalty revenues DUROLANE | 6.2 | 73.5 | - | 3.2 | 73.5 | - | 76.0 |
| Total revenues | 127.9 | 225.4 | -43% | 67.5 | 151.2 | -55% | 353.1 |
| Operating income | -27.8 | 62.2 | -145% | -17.9 | 70.8 | -125% | 24.3 |

Sales of goods within the product area decreased by 20 percent during the first six months of the year and amounted to 121.7 (151.9) MSEK, of which 64.3 (77.7) MSEK was during the second quarter. Operating income was -27.8 (-62.2) MSEK, of which -17.9 (70.8) was in the second quarter. Fluctuations in exchange rates negatively affected sales by -6.6 MSEK.



DEFLUX

Sales of DEFLUX amounted to 89.8 (99.5) MSEK during the first six months of the year, of which 46.7 (52.2) MSEK was during the second quarter. The decrease is primarily due to the American market, where a large insurance company has changed its policy with regard to endoscopic treatment of VUR. Work is ongoing to influence the wording of the guidelines that

form the basis of the decision. On the other hand, sales in Europe displayed good growth compared with the same period the previous year. Price increases have also been carried out in several markets in Europe.

DUROLANE

Sales of DUROLANE amounted to 21.9 (38.5) MSEK during the first six months of the year, of which 11.8 (19.6) was during the second quarter. Royalty revenues amounted to 6.2 (73.5) MSEK. A comparison of revenues from the two periods is misleading both as a consequence of the fact that sales of DUROLANE have gradually been transferred to Smith & Nephew since the fourth quarter of 2006 and also due to the fact that Q-Med received a one-time payment of 73.5 MSEK in June 2006 in connection with the signing of the agreement with Smith & Nephew. The agreement with Smith & Nephew means that the main source of revenue for Q-Med will be constituted by royalty payments based on Smith & Nephew's sales of products within the framework of the collaboration. The registration process for DUROLANE is ongoing in the USA. Together with Smith & Nephew, Q-Med has begun a market study that is to comprise just over 400 patients.

ZUIDEX

Sales of ZUIDEX amounted to 9.4 (13.9) MSEK during the first six months of the year, of which 5.2 (5.9) MSEK was during the second quarter. In the middle of July the first summary of the results from the North American clinical study on ZUIDEX was completed. According to the study both treatment with ZUIDEX and treatment with the comparative product displayed improvement, but the primary objective was not met. The data will be further analyzed, but Q-Med's assessment is that the study results are not sufficiently good to successfully support an application for market approval in the USA.

SOLESTA

The product is being introduced in Europe through a small number of specialists. A study is ongoing in the USA, Canada and Europe before the registration process in the USA.

COSMOFER

Sales of Cosmofer started in December last year. Just over 30 hospitals have bought the product since sales were started. The guidelines of the Swedish Renal Association concerning the treatment of patients with kidney disease have been applied to Cosmofer since April.

DEVELOPMENT PROJECTS

Most of the research and development that does not as yet generate any sales is included within Development Projects.

| (MSEK) | Januari - June | | | April - June | | | Whole year |
|------------------|----------------|-------|-------|--------------|-------|-------|------------|
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | 2006 |
| Operating income | -10,4 | -18,7 | n/a | -5,9 | -10,1 | n/a | -40,4 |

The product area has not generated any revenues. Operating income amounted to -10.4 (-18.7) MSEK during the first six months of the year, of which -5.9 (-10.1) MSEK was during the second quarter.

PARENT COMPANY

Sales in the Parent Company, Q-Med AB (publ), amounted to 501.7 (424.0) MSEK, including sales of 205.5 (137.6) MSEK to affiliated companies. Income after financial items amounted to 162.1 (183.4) MSEK. The Parent Company's liquid funds at June 30, 2007 amounted to 201.7 (359.1) MSEK.

PERSONNEL

The number of employees increased by 70 people during the period and amounted to 678 (582) at June 30, 2007, including 454 (386) in Sweden.

PROSPECTS FOR THE FUTURE

The market for injectable esthetic products is continuing to grow. Q-Med continues to be positive in its assessment of the demand situation with regard to RESTYLANE in all regions both in the short term and the long term, despite increased competition. The aim of the company is to defend its strong position, with a retained or increased market share in all the principal markets. In parallel new growth markets will be developed, primarily in Asia and Latin America. The work on broadening the product portfolio is continuing; body contouring and hydro balance are prioritized areas. New generations of products based on botulinum toxin are to be developed in collaboration with Medy-Tox Inc.

Q-Med also anticipates growth within the Hospital Healthcare product area. The establishment of ZUIDEX in Europe continues.

DEFLUX is being given increased priority by the sales organization so that the company will be able to take advantage of the leading position that the product has achieved as the primary method of treatment for VUR. The work on changing the wording of the guidelines that form the basis of the decision concerning treatment alternatives for VUR in the USA will give results at the earliest during the first half of 2008.

For DUROLANE it is too early to assess how quickly the collaboration with Smith & Nephew will have an impact. The development of DUROLANE also depends on the result of the registration process in the USA.

Q-Med's overall objective is unchanged: continued high growth together with good profitability.

| Group income statement (MSEK) | January - June | | | April - June | | | Whole year 2006 |
|---|----------------|--------------|------------|--------------|--------------|-------------|-----------------------|
| | 2007 | 2006 | +/- % | 2007 | 2006 | +/- % | |
| Revenues from sales of goods | 658.8 | 612,7 | 8% | 361.5 | 330.5 | 9% | 1,227.6 |
| Royalty revenues | 6.2 | 73,5 | - | 3.2 | 73.5 | -96% | 76.0 |
| Total revenues | 665.0 | 686,2 | -3% | 364.7 | 404.0 | -10% | 1,303.6 |
| Cost of goods sold | -93.7 | -83,2 | 13% | -49.0 | -43.4 | 13% | -183,6 |
| Gross income | 571.3 | 603,0 | -5% | 315.7 | 360.6 | -12% | 1,120.0 |
| Other operating revenues | 207.9 | 3,8 | n/a | 203.0 | 1.5 | n/a | 9.8 |
| Selling expenses | -265.1 | -247,8 | 7% | -142.2 | -131.5 | 8% | -522.9 |
| Administrative expenses | -53.6 | -44,4 | 21% | -27.6 | -27.7 | 0% | -92.0 |
| R&D costs | -139.8 | -95,3 | 47% | -86.9 | -42.4 | 105% | -202.4 |
| Other operating expenses | -2.5 | -6,4 | -61% | 0.1 | -3.6 | -103% | -12.6 |
| Operating income | 318.2 | 212,9 | 49% | 262.1 | 156.9 | 67% | 299.9 |
| Result from financial items | 3.1 | 2,0 | 55% | -0.8 | 1.0 | n/a | 8.1 |
| Income after financial items | 321.3 | 214,9 | 50% | 261.3 | 157.9 | 65% | 308.0 |
| Tax on income for the period | -37.3 | -63,5 | -41% | -19.0 | -45.5 | -58% | -95.7 |
| Net income for the period | 284.0 | 151,4 | 88% | 242.3 | 112.4 | 116% | 212.3 |
| Earnings per share, SEK* | 2.86 | 1,53 | | 2.44 | 1.13 | | 2.14 |
| Earnings per share after full dilution, SEK | 2.86 | 1,53 | | 2.44 | 1.13 | | 2.14 |
| Number of outstanding shares at closing day | 99,374,001 | 99,265,372 | | 99,374,001 | 99,265,372 | | 99,349,329 |
| Average number of outstanding shares | 99,369,889 | 99,257,791 | | 99,374,001 | 99,256,022 | | 99,275,590 |

* Earnings per share is defined as the earnings for the period in relation to the average number of outstanding shares for the period.

| Other key ratios | January - June | | Whole year 2006 |
|---|----------------|-------|--------------------|
| | 2007 | 2006 | |
| Gross margin | 85.8% | 86.4% | 85.0% |
| Operating margin | 47.9% | 34.7% | 23.0% |
| Operating margin before R&D costs | 68.9% | 50.3% | 38.5% |
| Number of employees | 678 | 582 | 608 |
| Equity/assets ratio | 79.4% | 78.6% | 78.3% |
| Shareholders' equity per share, SEK | 13.46 | 11.94 | 12.56 |
| Shareholders' equity per share after full dilution, SEK | 13.46 | 11.94 | 12.56 |

Group balance sheet

| (MSEK) | June 30, 2007 | June 30, 2006 | Dec 31, 2006 |
|---|------------------|------------------|-----------------|
| Fixed assets | | | |
| Patents and other intellectual property | 28.0 | 28.9 | 26.7 |
| Goodwill | 42.3 | 42.2 | 41.4 |
| Tangible assets | 678.1 | 573.6 | 645.7 |
| Deferred tax asset | 20.2 | 10.9 | 11.2 |
| Other financial assets | 13.6 | 12.5 | 13.0 |
| Current assets | | | |
| Inventories | 138.7 | 101.6 | 106.1 |
| Accounts receivable | 241.0 | 245.8 | 207.9 |
| Other current receivables | 9.0 | 17.0 | 15.4 |
| Prepaid expenses and accrued revenues | 33.7 | 54.4 | 56.7 |
| Liquid funds | 479.5 | 421.8 | 470.3 |
| Total assets | 1 684.1 | 1,508.7 | 1,594.4 |
| Shareholders' equity | 1,337.3 | 1,185.6 | 1,248.0 |
| Long-term liabilities | | | |
| Interest-bearing long-term liabilities | 50.0 | 50.0 | 50.0 |
| Provisions | 6.9 | 5.4 | 7.6 |
| Deferred tax liability | 83.9 | 69.5 | 79.0 |
| Current liabilities | | | |
| Interest-bearing current liabilities | 23.7 | 23.9 | 23.4 |
| Accounts payable | 52.8 | 54.8 | 53.8 |
| Other interest-free current liabilities | 54.6 | 50.4 | 64.1 |
| Accrued expenses and prepaid revenues | 74.9 | 69.1 | 68.5 |
| Total liabilities and shareholders' equity | 1,684.1 | 1,508.7 | 1,594.4 |
| <hr/> | | | |
| Pledged assets for own liabilities | 55.6 | 55.6 | 55.6 |
| Contingent liabilities | none | none | none |

| Change in shareholders' equity during the period (MSEK) | January - June 2007 | | January - June 2006 | |
|---|---|--|---|--|
| | Attributable to Parent Company's shareholders | | Attributable to Parent Company's shareholders | |
| Opening balance | 1,248.0 | | 1,112.0 | |
| Translation difference | 2.9 | | -4.0 | |
| Net income for the period | 284.0 | | 151.4 | |
| New share issue | 1.1 | | 0.5 | |
| Dividend | -198.7 | | -74.4 | |
| Closing balance | 1,337.3 | | 1,185.5 | |

| Group cash flow analysis (MSEK) | January - June 2007 | | April - June 2006 | |
|---|---------------------|--------------|-------------------|--------------|
| | 2007 | 2006 | 2007 | 2006 |
| Cash flow from operating activities* | 64.6 | 108.4 | 61.3 | 97.8 |
| Cash flow from investing activities | 138.9 | -67.4 | 163.2 | -36.8 |
| Cash flow from financing activities | -197.6 | -73.9 | -198.7 | -74.2 |
| Cash flow for the period | 5.9 | -32.9 | 25.8 | -13.2 |
| Liquid funds at beginning of period | 470.3 | 458.2 | 453.4 | 436.8 |
| Exchange rate differences in liquid funds | 3.3 | -3.5 | 0.3 | -1.8 |
| Liquid funds at end of period | 479.5 | 421.8 | 479.5 | 421.8 |
| * Of which change in working capital | -21.7 | -77.3 | -3.8 | -61.3 |

ACCOUNTING PRINCIPLES

This quarterly report has been drawn up in accordance with IAS 34, Interim Financial Reporting, which is in accordance with the requirements of the recommendation of the Swedish Financial Accounting Standards Council, RR31.

The accounting principles that are applied in this interim report are those described in the notes in the Annual Report for 2006.

ASSURANCE OF THE BOARD

The Board and the President and CEO hereby assure that the half-year report gives a true and fair overview of the company's business, financial position and results.

July 26, 2007
Uppsala

Q-Med AB (publ)

Pia Rudengren
Chair of the Board

Håkan Edström

Bertil Hult

Anders Milton

Åsa Rödén

Pernilla Ström

Bengt Ågerup
President and CEO

Queries should be addressed to:

Bengt Ågerup, President and CEO

Tel: +46 (0)70-974 9025

Erika Kjellberg Eriksson, Vice President and CFO

Tel: +46 (0)70-974 9020

Madelene Sandgren, Director Investor Relations and Corporate Communications

Tel: +46 (0)70-974 9015

Coming reports

Interim report January – September 2007

October 23, 2007